Sign up to save your podcasts
Or
Share Enzyvant, Charles River Laboratories, Merck (again), Regeneron
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Enzyvant, Charles River Laboratories, Merck (again), Regeneron
The 26-year pipeline, CMDO divestment, oncology, and movement among COVID19 Therapies
Originally Published as The Niche Podcast.
Find out more at
https://LifeScienceTodayPodcast.com
Story References
https://tinyurl.com/Niche-073-1
https://tinyurl.com/Niche-073-2
https://tinyurl.com/Niche-073-3
https://tinyurl.com/Niche-073-4
https://tinyurl.com/Niche-073-5
https://tinyurl.com/Niche-073-6
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
View all episodes
By Noah Goodson, PhD
5
77 ratings
The 26-year pipeline, CMDO divestment, oncology, and movement among COVID19 Therapies
Originally Published as The Niche Podcast.
Find out more at
https://LifeScienceTodayPodcast.com
Story References
https://tinyurl.com/Niche-073-1
https://tinyurl.com/Niche-073-2
https://tinyurl.com/Niche-073-3
https://tinyurl.com/Niche-073-4
https://tinyurl.com/Niche-073-5
https://tinyurl.com/Niche-073-6
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.